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A B ST R AC T  
 
Aim: To compare our parameters as regards: i) cell count via two different automated cell count 
techniques, and ii) viability via automated trypan blue exclusion and 7-aminoactinomycin D (7-AAD) 
staining. 
Method: We used the trypan blue exclusion technique and an automated cell counter and for viability 
testing, and the trypan blue exclusion technique and the 7-AAD evaluation by flow cytometry. The 
trypan blue exclusion and the radio frequency techniques were used for automated cell counting. Flow 
cytometric analysis was performed by evaluating the yielded cellular products for 7-AAD uptake 
during the cell count of CD34+ cells. 
Results: The mean values for cell count were estimated as 3.44±1.22x106/ml (range, 2.48-
5.71x106/ml) and 4.14±1.94x106/ml (range, 1.77-7.43x106/ml) for the trypan blue exclusion and 
radio frequency techniques, respectively. Additionally, the mean values for viability analyses via the 
automated trypan blue exclusion and 7-AAD were 93.38±6.09% (range, 79.00-98.00%) and 
99.49±0.60% (range, 98.40-100.00%), respectively. 
Conclusions: Our study has responded to two fundamental questions: whether the results of both of 
the automated techniques for cell count correspond with each other, and whether the results of the 
automated viability assessment conform those of the 7-AAD technique during the manufacturing 
processes of cellular therapy products intended for clinical use. Even though we have the opportunity 
to use the hemocytometer in our laboratory setting, the automated trypan blue exclusion technique 
gives cell count results in concordance within the range of the expectations of our Quality 
Management System (QMS). 
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Promising to be first-line therapy for many 
kinds of different diseases in the future, cellular 
therapies are gradually expanding as a 
treatment option in many clinics. Cellular 
therapies can be bluntly defined as in vitro-
manipulated human cells which require certain 
safety and quality parameters as prerequisites – 
two of which are cell count and viability– at the 
time of release from the laboratory to the clinic.  
Cell counting techniques can either be 
performed manually (e.g. hemocytometer) or 
by the use of automatic devices which are 
operated by certain principles such as the 
automated trypan blue exclusion [1,2] and radio 
frequency [3,4]. Viability assessment is also 
possible via the trypan blue exclusion technique 
[5]. Also some manual methods– i.e. acridine 
orange, eosin staining can be used for viability 
detection [6]. Alternatively, the viability dye 7-
aminoactinomycin D (7-AAD) can also be used 
to determine the number of viable CD34+ cells 
[7,8]. In this manner, automated techniques 
present themselves to be utile in performing 
both cell count and viability estimation, and 
when necessary being able to give both results 
realtime.  
Previously, researchers made various 
comparisons of manual and automated cell 
count and viability techniques in different cell 
types [2,5,6,9-11]. However, none of these 
studies show comparison between automatic 
and/or manual cell count and viability 
techniques by means of hematopoietic 
progenitor cells. In this study, we aimed to 
compare our parameters as regards: cell count 
via two different automated cell count 
techniques, and ii) viability via automated 
trypan blue exclusion and 7-AAD staining. As 
noticed, studies practicing the comparison of 
different automated cell counting methods on 
human stem cells have not yet been performed.  
Under the scope of the current Good 
Manufacturing Practices (cGMP) activities at 
Ankara University Stem Cell Institute Tissue 
and Cell Manufacturing Center, we obtained 
purified CD34+ hematopoietic stem cell 
products intended for use in patients mainly 
suffering from severe combined immune 
deficiency (SCID). We had previously reported 
our local experience with the CliniMACS 
(magnetic-activated cell separation system) in 
hematologic malignancies and immune failure 
disease. There, we evaluated our CliniMACS 
CD34+ cell enrichment process by revealing 
absolute cell count and viability besides other 
parameters for the end products [12]. This study 
has two objectives: one is to determine whether 
the two automated techniques’ results for cell 
count match each other, and whether the 
automated cell counter results for viability 
match those of the 7-AAD technique during the 
manufacturing processes of cellular therapy 
products intended for clinical use. This is the 
first time that hematopoietic progenitor cell 
count and viability testing are compared 
between different automated techniques in 
order to suggest automated cell counters as 
simple-use devices with the ability to produce 
reliable and timely results. 
 
Materials and Methods 
As defined in the study of Kilic et al. [12], the 
apheresis products were transferred from 
Ankara University School of Medicine İbn-i 
Sina Hospital Therapeutic Apheresis Unit 
Center to our Tissue and Cell Manufacturing 
Center, within a sterile container, with the 
facility to transport at a stable temperature 
recorded by a data logger [12]. The records 
containing the results of complete blood count 
(CBC), CD34+ cell enumeration and viability 
obtained by flow cytometric evaluation were 
accompanied with each sample The study was 
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approved by the Turkish Ministry of Health 
Turkish Medicines and Medical Devices 
Agency, with the approval number 2014/2 for 
manufacturing of human medical products. The 
research was conducted ethically in accordance 
with the World Medical Association 
Declaration of Helsinki. Written informed 
consent was collected from each subject. 
Samples were used to perform 8 separate 
CliniMACS CD34+ enrichment process cycles. 
The enrichment process was carried out as 
described in the CliniMACS® User Manual 
(CliniMACS User Manual), and was followed 
in accordance with the study of Leong et al. [9]. 
The CD34+ cell selection technique is used to 
deplete T cells from collected human-based cell 
products before allogeneic HSC 
transplantation. The CD34+ cells can be 
separated by various devices, one of which is 
the CliniMACS (Miltenyi, Biotec, GmbH, 
Bergish, Gladbach, Germany) [9,12-14]. The 
CliniMACS CD34+ cell enrichment process is 
performed within the Quality Management 
System of our Tissue and Cell Manufacturing 
Center, as described by Kilic et al. [12]. Cell 
count and viability are the most critical release 
criteria besides other tests, such as sterility and 
endotoxin testine, for each CD34+-enriched 
end product. In the 8 cell count processes 
included in this study, we used the trypan blue 
exclusion technique and an automated cell 
counter for cell count, and for viability testing, 
the trypan blue exclusion technique and the 7-
AAD evaluation by flow cytometry [12].  
 
Cell count 
Automated cell count via trypan blue 
exclusion 
In the beginning, the trypan blue exclusion test 
was performed by the use of the TC20™ 
Automated Cell Counter [1]. This device 
provides cell counts within the range of 5×104 
to 1×107 cells/ml [2]. Twenty microliters of the 
0.04% trypan blue staining solution and 20 μL 
of each sample were mixed within the test tube. 
Ten microliters taken from this mixture was 
pipetted and placed on the counting chamber. If 
the cell number exceeded 1×107 cells/ml, the 
samples were diluted with saline solution at the 
ratio of 1:9, and the count was repeated 
thereafter [6].  
 
Automated cell count via radio frequency 
The radio frequency principle was used as the 
second automated cell count technique 
(Sysmex Europe GmbH. Sysmex XN-3000). 
Devices operating under such principle are only 
certified for testing blood samples, hence do not 
guarantee use of other bodily fluids. The 
Sysmex XN-3000 is a fully automated 
complete blood count (CBC) hematology 
analyzer including 6-part differential count. 
This analyzer differentiates white blood cells 
(WBC) and tests 28 standard diagnostic CBC 
parameters.  The XN-3000 processes 200 
samples/hour and includes the SP-10 
slidemaker/stainer for reflexive slide 
preparation [15]. Cells in an aliquot (1 cc) of 
each of the end products were automatically 




Automated cell counter via trypan blue 
exclusion 
Viability was assessed via an automated cell 
counter, using the trypan blue exclusion 
technique [1]. The automated device was used 
after preparation of samples as explained in 
section “2.1.1 Automated Cell Count via 
Trypan Blue Exclusion”. In this technique, the 
automated cell counter detects the dead cells, 
which are instantly stained with the trypan blue, 
within the total cell population. The viability of 
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the cells is displayed on the screen in terms of 
percentage of viability. 
The 7-aminoactinomycin dye (7-AAD) method 
Flow cytometric analysis was performed at 
Ankara University Hematology Laboratory as 
explained in the studies of Varan et al. [6] and 
Kilic et al. [12].  Briefly, the yielded cellular 
products were evaluated for 7-AAD uptake 
during the flow cytometric count of CD34+ 
cells. At the end of the CD34+ enrichment 
process, the end products were evaluated for 
cells expressing CD34 and also for CD45, CD3 
CD56, CD19, and CD14 to further characterize 
the cell content of the product. Cell viability 
was checked for each sample using the viability 
dye 7-AAD, and all counts were reported in 
terms of viable cells. The Kaluza software 
ver2.1 (Beckman Coulter Miami, USA) was 
used to analyze the collected data using the 
Navios 3L10C device (Beckman Coulter 
Miami, USA).  CD34+ cell counts were 
calculated according to the single platform 
ISHAGE protocol [16]. The statistical data of 
the charts were retrieved from the statistical 
results of the report and the ratio of dead cells 
(cells stained with 7-AAD) was determined. 
The percentage of living cells was determined 
by subtracting the percentage of dead cells from 
100. 
Statistics analysis 
Statistical analysis was performed by using the 
SPSS 22 version package program. Correlation 








obtained from different methods, were tested 




An example of three consecutive cell count and 
viability results obtained by our automated cell 
counter is presented in Figure 1. 
The distribution of the cells was checked in 
two-dimensional dot plot graph (SSC vs 7-
AAD) and upon gating of 7-AAD unstained 
viable cells this gate was applied to a CD45-
SSC dot plot graph (Figure 2). 
Cell count and viability results for the CD34+ 
end products are summarized in Table 1. 
Mean values for cell count were estimated as 
3.44±1.22x106/ml (range, 2.48-5.71x106/ml) 
and 4.14±1.94x106/ml (range, 1.77-
7.43x106/ml) for the trypan blue exclusion and 
radio frequency tests, respectively. 
Additionally, viability mean values for the 
automated trypan blue exclusion and 7-AAD 
were 93.38±6.09% (range, 79.00-98.00%) and 




Automated techniques facilitate the work load 
of researchers by requiring less time for 
analysis and no need for complementary 
devices, and leave negligible effort. There is 
debate about the efficiency between the current 











Figure 1. An example of three consecutive cell count and viability results obtained by the use of the automated 
cell counter. 
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Figure 2.   Before starting the  enrichment of the hematopoietic stem cells; CD34+ cell count was  performed  
using the ISHAGE protocol: A: The artifacts were eliminated  from the leukocytes, B: The viable cells that were 
unstained were selected, C: CD45+ cells were selected from viable cells, D: CD34+ cells among viable CD45+ 
cells were marked, E: CD45dim+cells were selected from CD45+ and CD34+ viable cells and upon checking for 
particles smaller than lymphocytes (unseen) the actual viable CD34+ cell numbers were detected. As seen in F, 
non-adhered beads, pipetted into the same tube, were selected and used for the absolute count of CD34+ cells 
using the single platform analysis. 
Table 1. Cell count and viability results by means of the two automated cell count techniques, and by means of 
an automated cell counter and flow cytometric evaluation by 7-AAD.  
 
 Cell Count Viability 
Automated 










1 2.80 3.46 95.00 99.00 
2 2.63 3.00 98.00 99.50 
3 2.60 3.50 92.00 99.90 
4 4.87 4.97 94.00 100.00 
5 3.68 7.43 96.00 99.10 
6 2.71 1.77 79.00 98.40 
7 2.48 2.68 96.00 100.00 
8 5.71 6.34 97.00 100.00 
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been addressed in a number of studies. The use 
of such techniques force the researchers to 
analyze the reliability of the automated 
systems. A number of previous studies have 
compared the various cell count and viability 
assessment methods [5,6,9-11,17]. 
Several studies have focused on cell count and 
viability of human cells. Leong et al. [9] used 
the flow cytometry technique for counting 
CD34+-selected hematopoietic stem cells and a 
manual trypan blue exclusion technique via the 
Neubauer chamber for viability assessment. We 
analyzed the same kind of cells and used the 7-
AAD for viability assessment. However, while 
they prefered the manual technique for trypan 
blue exclusion, we used an automated cell 
counter. In the study of Leong et al. [9], the 
CD34+-selected products showed a median 
viability of 98%. (range 92 - 99%). We found 
only one published study which specifically 
addresses comparison of various techniques for 
cell count. Nevertheless, this study was not 
performed on human stem cells [11]. Until 
today, only two reports have studied the 
techniques on human stem cells on a viability 
perspective [6,17]. 
With the trypan blue exclusion method, Humpe 
et al. [17] detected the mean viability as 95.8% 
(range, 72.6%-98.7%) for 8 patients, with slight 
similarity to our automated viability results, 
93.38±6.09% (range, 79.00-98.00%). Like us, 
Varan et al. [6] studied the comparison of 
viability results belonging to hematopoietic 
progenitor cells in 20 samples by trypan blue 
uptake and measurement of 7-AAD staining by 
flow cytometry. However, no remarks were 
made on cell count [6]. The median viability 
obtained by the 7-AAD was 78±16%, much 
lower from our 7-AAD results, of 99.49±0.60% 
(range, 98.40-100.00%). The Intraclass 
Correlation Coefficient (ICC) between the 
trypan blue and 7-AAD methods was found as 
0.47 (p > 0.05) in the study Varan et al. [6], and 
no statistically significant concordance was 
detected. In our study, no significant correlation 
was detected between viability results obtained 
by the two different techniques, the automated 
cell counter and the 7-AAD. Reich-Slotky et al. 
[10] determined the number of CD34+ cells by 
flow cytometry and the viability by trypan blue 
uptake and by the measurement of 7-AAD 
staining using flow cytometry. The average 
viability was 98.8% with trypan blue exclusion, 
and 97.0% with 7-AAD [10]. Our study 
suggested mean values of viability obtained by 
the automated cell counter as 93.38±6.09% 
(range, 79.00-98.00%) and of 7-AAD as 
99.49±0.60% (range, 98.40-100.00%). Such 
values were respectively lower and higher than 
that of Reich-Slotky et al. [10]. These findings 
are controversial and thus make it questionable 
as to which method would be more reliable.  
Previously, there have been different results 
comparable with ours obtained from 
mammalian cell types of non-human origin. 
Similar with our study, Camacho-Fernández et 
al. [11] performed cell counting by comparing 
manual and automated techniques in isolated 
eggplant microspore cultures. This study is 
significant as it has compared several 
techniques for cell count.  In our study, when 
the two different automated cell counters were 
compared by means of cell count results, a 
significant correlation value of 0.72 was 
observed, in concordance with that of 
Camacho-Fernández et al. [11]. On the other 
hand, Kwizera et al. [5] counted Cryptococcus 
yeast cells in cerebrospinal fluid culture by 
trypan blue staining and rapidly quantified 
viable cells with an automated cell counter. The 
study of Kwizera et al. [5] is the first article 
practicing the comparison of different 
automated cell counting methods on human 
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stem cells and mainly focusing on the 
validation of the repeatability of results.  
Although human donor-based, cellular 
therapies are classified as human medicinal 
products, they differ from the conventional 
medicines in the sense that each batch release is 
equivalent to one donor per manufacture. In this 
manner, it is not so easy to reach high sample 
sizes as it would be for serial manufacturing. 
Additionally, one end user, a patient, has to be 
matched with the appropriate donor in order to 
start manufacturing a cellular therapy product. 
This does not always happen in a serial manner, 
which also contributes to the bottleneck of 
reaching high sample sizes. In the setting of our 
study, the current sample size for hematopoietic 
stem cell manufacturing is 8. We plan further 
studies to enhance this sample size and continue 
our studies in depth. 
 
Conclusion 
In conclusion, our study has responded to two 
questions at the same time: whether the results 
of both automated techniques for cell count 
correspond with each other, and whether the 
results of the automated viability assessment 
conform those of the 7-AAD technique when 
manufacturing cellular therapy products 
intended for clinical use. Even though we have 
the opportunity to use the hemocytometer in our 
laboratory setting, the automated cell counter 
that make use of trypan blue exclusion gives the 
cell count results in concordance within the 
range of the expectations of the Quality 
Management System (QMS) of our Tissue and 
Cell Manufacturing Center. However, for 
viability results, the 7-AAD technique, which is 
already validated at our premises, might be 
more accurate when products are intended for 
clinical use. 
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